See more : Mitsui DM Sugar Holdings Co.,Ltd. (2109.T) Income Statement Analysis – Financial Results
Complete financial analysis of Tourmaline Bio, Inc. (TRML) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tourmaline Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bioxyne Limited (BXN.AX) Income Statement Analysis – Financial Results
- Ichigo Inc. (2337.T) Income Statement Analysis – Financial Results
- Credit Suisse High Yield Bond Fund, Inc. (DHY) Income Statement Analysis – Financial Results
- BM Technologies, Inc. (BMTX) Income Statement Analysis – Financial Results
- High Peak Royalties Limited (HPR.AX) Income Statement Analysis – Financial Results
Tourmaline Bio, Inc. (TRML)
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.00K | 6.00K | 623.00K | 447.00K | 379.00K |
| Gross Profit | -33.00K | -6.00K | -623.00K | -447.00K | -379.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.37M | 17.53M | 212.00 | 15.28M | 13.37M |
| General & Administrative | 13.04M | 2.18M | 692.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.04M | 2.18M | 692.00 | 6.96M | 4.63M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.41M | 19.70M | 904.00 | 22.24M | 18.00M |
| Cost & Expenses | 45.41M | 19.70M | 904.00 | 22.68M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 223.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 23.00K | 0.00 |
| Depreciation & Amortization | 33.00K | 6.00K | 904.00 | 447.00K | 379.00K |
| EBITDA | -45.38M | -19.70M | -46.88M | -22.24M | -17.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.41M | -19.70M | -904.00 | -22.68M | -18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.29M | 0.00 | -47.83M | -23.00K | 223.00K |
| Income Before Tax | -42.12M | -19.70M | -904.00 | -22.71M | -18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | -47.21M | 0.00 | 0.00 |
| Net Income | -42.12M | -19.70M | -904.00 | -22.71M | -18.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.87 | -0.97 | 0.00 | -33.97 | -4.39 |
| EPS Diluted | -8.87 | -0.97 | 0.00 | -33.97 | -4.39 |
| Weighted Avg Shares Out | 4.75M | 20.34M | 10.88M | 668.51K | 4.13M |
| Weighted Avg Shares Out (Dil) | 4.75M | 20.34M | 10.88M | 668.51K | 4.13M |
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will...
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD,...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the...
Tourmaline Bio to Present at Upcoming Investor Conferences
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is...
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as...
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by...
Source: https://incomestatements.info
Category: Stock Reports